Literature DB >> 19735675

Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif.

Sonia Moretti1, Valentina De Falco, Anna Tamburrino, Flavia Barbi, Maria Tavano, Nicola Avenia, Fausto Santeusanio, Massimo Santoro, Antonio Macchiarulo, Efisio Puxeddu.   

Abstract

BRAF gene mutations have been associated with human cancers. Among the naturally occurring mutations, two that involve amino acids of the conserved DFG motif in the activation loop (D594V and G596R), appear to be inactivating. Aim of this study was to analyze the molecular mechanisms involved in the loss of function of B-Raf inactivating mutation G596R. Furthermore, the ability of the B-Raf DFG motif mutants to generate heterodimers with C-Raf and the possible functional consequences of the B-Raf/C-Raf heterodimer formation was examined. Wet molecular experiments in HEK293T cells demonstrate that B-Raf(G596R) is a kinase-impaired mutant. Molecular dynamics simulations show that the loss of function of B-Raf(G596R) depends on a restraining effect of Arg596 on the catalytic residue Asp594, which results in the loss of the appropriate spatial localization and/or conformation of the latter necessary for anchoring ATP to the enzyme. Exploration of B-Raf/C-Raf heterodimer formation indicates the occurrence of functioning heterodimers in the case of all the DFG B-Raf mutants, independently from the expected differences in spatial conformation of the activation loop, although the transforming activity of the mutants appear negligible. In conclusion, this study delivers novel information on the functional properties of the B-Raf DFG motif inactivating mutants and on the mechanisms driving B-Raf/C-Raf heterodimerization and consequent C-Raf transactivation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19735675     DOI: 10.1016/j.bbamcr.2009.09.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

Review 1.  Catalytic mechanisms and regulation of protein kinases.

Authors:  Zhihong Wang; Philip A Cole
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

2.  Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.

Authors:  Aishwarya Kundu; Jeanne G Quirit; Michelle G Khouri; Gary L Firestone
Journal:  Mol Carcinog       Date:  2016-02-15       Impact factor: 4.784

3.  Differentiated thyroid tumors: surgical indications.

Authors:  R Lucchini; M Monacelli; S Santoprete; R Triola; C Conti; R Pecoriello; P Favoriti; M S Di Patrizi; I Barillaro; A Boccolini; S Avenia; M D'Ajello; A Sanguinetti; N Avenia
Journal:  G Chir       Date:  2013 May-Jun

4.  Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.

Authors:  Georgios Antonios Margonis; Stefan Buettner; Nikolaos Andreatos; Yuhree Kim; Doris Wagner; Kazunari Sasaki; Andrea Beer; Christoph Schwarz; Inger Marie Løes; Maria Smolle; Carsten Kamphues; Jin He; Timothy M Pawlik; Klaus Kaczirek; George Poultsides; Per Eystein Lønning; John L Cameron; Richard A Burkhart; Armin Gerger; Federico N Aucejo; Martin E Kreis; Christopher L Wolfgang; Matthew J Weiss
Journal:  JAMA Surg       Date:  2018-07-18       Impact factor: 14.766

5.  HER2 activating mutations are targets for colorectal cancer treatment.

Authors:  Shyam M Kavuri; Naveen Jain; Francesco Galimi; Francesca Cottino; Simonetta M Leto; Giorgia Migliardi; Adam C Searleman; Wei Shen; John Monsey; Livio Trusolino; Samuel A Jacobs; Andrea Bertotti; Ron Bose
Journal:  Cancer Discov       Date:  2015-08       Impact factor: 39.397

6.  Identification and characterization of novel mutations in the human gene encoding the catalytic subunit Calpha of protein kinase A (PKA).

Authors:  Kristoffer Søberg; Anja C V Larsen; Mandy Diskar; Paul H Backe; Magnar Bjørås; Tore Jahnsen; Jon K Laerdahl; Torbjørn Rognes; Friedrich W Herberg; Bjørn S Skålhegg
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

7.  Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma.

Authors:  Valentina Condelli; Francesca Maddalena; Lorenza Sisinni; Giacomo Lettini; Danilo Swann Matassa; Annamaria Piscazzi; Giuseppe Palladino; Maria Rosaria Amoroso; Franca Esposito; Matteo Landriscina
Journal:  Oncotarget       Date:  2015-09-08

8.  Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways.

Authors:  Amanda Tse; Gennady M Verkhivker
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

9.  Rethinking the role of oncogenes in papillary thyroid cancer initiation.

Authors:  Mario Vitale
Journal:  Front Endocrinol (Lausanne)       Date:  2012-06-26       Impact factor: 5.555

10.  Structure-functional prediction and analysis of cancer mutation effects in protein kinases.

Authors:  Anshuman Dixit; Gennady M Verkhivker
Journal:  Comput Math Methods Med       Date:  2014-04-08       Impact factor: 2.238

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.